Issue 1/2016

Circulating cell-free DNAs and miRNAs as promising non-invasive biomarkers for early detection of gastric cancer (1 — 9)

X. LIU, K. M. CHU

DOI: 10.4149/neo_2016_002

Current antiangiogenic agents in oncology and ophthalmology (10 — 17)

M. CERNAK, L. NOGOVA

DOI: 10.4149/neo_2016_001

Circulating tumor cells in breast cancer patients (18 — 29)

B. BYSTRICKY, M. MEGO

DOI: 10.4149/neo_2016_003

Cathepsin L is involved in proliferation and invasion of breast cancer cells (30 — 36)

G. QIN, Y. CAI, J. LONG, H. ZENG, W. XU, Y. LI, M. LIU, H. ZHANG, Z. L. HE, W. G. CHEN

DOI: 10.4149/neo_2016_004

In vitro and in vivo antitumor activity of a novel chlorin derivative for photodynamic therapy (37 — 43)

C. Y. ZHANG, L. J. ZHANG, J. W. LI, J. H. LI, Z. M. WU, L. X. ZHANG, N. CHEN, Y. J. YAN, Z. L. CHEN

DOI: 10.4149/neo_2016_005

MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition (44 — 56)

H. WANG, M. SANG, C. GENG, F. LIU, L. GU, B. SHAN

DOI: 10.4149/neo_2016_006

Identification of driver pathways in cancer based on combinatorial patterns of somatic gene mutations (57 — 63)

H. T. LI, J. ZHANG, J. XIA, C. H. ZHENG

DOI: 10.4149/neo_2016_007

IARS2 silencing induces non-small cell lung cancer cells proliferation inhibition, cell cycle arrest and promotes cell apoptosis (64 — 71)

J. YIN, W. LIU, R. LI, J. LIU, Y. ZHANG, W. TANG, K. WANG

DOI: 10.4149/neo_2016_008

10-Hydroxycamptothecin induces apoptosis in human neuroblastoma SMS-KCNR cells through p53, cytochrome c and caspase 3 pathways (72 — 79)

Z. F. YUAN, Y. M. TANG, X. J. XU, S. S. LI, J. Y. ZHANG

DOI: 10.4149/neo_2016_009

The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo (80 — 92)

R. BAI, T. DING, J. ZHAO, S. LIU, L. ZHANG, X. LAN, Y. YU, L. YIN 

DOI: 10.4149/neo_2016_010

Clinical significance of angiopoietin-like protein 3 expression in patients with glioblastoma (93 — 98)

P. F. WANG, H. L. LI, X. QI, K. YAO, S. HAN, N. LIU, Y. K. YANG, S. W. LI, C. X. YAN

DOI: 10.4149/neo_2016_011

The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma (99 — 106)

W. MAJEWSKI, M. TABOR, P. BANASZEK, G. GLOWACKI, W. ROKICKI, A. TUKIENDORF

DOI: 10.4149/neo_2016_012

Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a non-endemic eastern european population (107 — 114)

M. SVAJDLER JR, J. KASPIRKOVA, R. MEZENCEV, J. LACO, T. TORDAY, P. DUBINSKY, L. STRAKA, O. ONDIC, M. MICHAL, A. SKALOVA

DOI: 10.4149/neo_2016_013

Loss at 16q22.1 identified as a risk factor for intrahepatic recurrence in hepatocellular carcinoma and screening of differentially expressed genes (114 — 120)

L. CHEN, Z. Z. ZHU, S. F. LIU, X. WAN, B. J. WEN, H. JIANG, J. ZHU, W. M. CONG

DOI: 10.4149/neo_2016_014

Supernatant versus exosomal urinary microRNAs. Two fractions with different outcomes in gynaecological cancers (121 — 132)

L. ZAVESKY, E. JANDAKOVA, R. TURYNA, L. LANGMEIEROVA, V. WEINBERGER, L. MINAR

DOI: 10.4149/neo_2016_015

Clinical significance of survivin and vascular endothelial growth factor mRNA detection in the peripheral whole blood of breast cancer patients (133 — 140)

S. WANG, J. XU, Q. ZHANG

DOI: 10.4149/neo_2016_016

Altered levels of plasma chemokines in breast cancer and their association with clinical and pathological characteristics (141 — 149)

D. NARITA, E. SECLAMAN, A. ANGHEL, R. ILINA, N. CIREAP, S. NEGRU, I. O. SIRBU, S. URSONIU, C. MARIAN

DOI: 10.4149/neo_2016_017

Prognostic significance of the Musashi-2 (MSI2) gene in childhood acute lymphoblastic leukemia (150 — 157)

H. Z. ZHAO, M. JIA, Z. B. LUO, Y. P. CHENG, X. J. XU, J. Y. ZHANG, S. S. LI, Y. M. TANG

DOI: 10.4149/neo_2016_018

Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test (158 — 162)

B. L. QU, B. N. CAI, W. YU, F. LIU, Y. R. HUANG, Z. J. JU, X. S. WANG, G. M. OU, L. C. FENG

DOI: 10.4149/neo_2016_019

Prediction of toxicities of prostate cancer radiotherapy (163 — 168)

B. HOSTOVA, P. MATULA, P. DUBINSKY

DOI: 10.4149/neo_2016_020